Peptide Price Finder

Home · Research · Longevity & bioregulators

Livagen research

What published studies found for Livagen: 12 papers, 0 in humans, with sample sizes and key results.

D
Little or no evidence
Why: Almost entirely cell studies (cultured lymphocytes, liver tissue) with a single rat study; no clinical outcomes in people or animals.

Livagen (the tetrapeptide Lys-Glu-Asp-Ala) has been studied mainly by Russian and Georgian groups in cultured lymphocytes from elderly people and patients, where it decondenses chromatin and reactivates ribosomal genes, plus some rat liver and enzyme work. These are laboratory measurements on cells rather than clinical trials, and no study reports a health outcome in people.

✓ 8 positive~ 2 mixed? 2 inconclusive

No clinical trials; the human-derived data are laboratory measurements on cultured cells, so there is no human safety data.

US compounding: Not compoundable. Not an FDA-approved drug and not nominated for FDA's 503A bulks list, so US pharmacies can't legally compound it. Status for every peptide.

Browse and filter these papersLivagen prices and vendors

Reviews

? InconclusivereviewAdv Gerontol · 2020

[The influence of polypeptide liver complex and tetrapeptide KEDA on organism physiological function in norm and age-related pathology.].

No new dataNarrative review

A review of a liver polypeptide complex and the KEDA (Livagen) peptide reports efficacy in animal and in vitro liver-injury models, without clinical trial data.

Studied
Liver polypeptide complex (Ventvil) and KEDA tetrapeptide (Livagen); animal and in vitro models of liver pathology
Main outcome
Hepato-, immuno-protective and antiageing effects
Authors' conclusion
Ventvil and KEDA peptide normalized immune and antioxidant status and restored liver function in experimental hepatitis, with maximal effects in aging.
Limitations
Review of experimental animal and in vitro data.
PubMed 32362099

Animal & lab studies

~ MixedanimalAdv Gerontol · 2005

[Effect of peptide Livagen on activity of digestive enzymes in gastrointestinal tract and non-digestive organs in rats of different ages].

Humans and animalsIn vitro enzyme assay plus two weeks of oral Livagen in rats2 weeks

In rats, two weeks of oral Livagen lowered digestive enzyme activity in young animals and raised it in old animals, bringing old-rat values closer to young controls.

Key resultIn vitro, Livagen reduced glycil-L-leucinedipeptidase activity in small intestine by 50%
Studied
Young and old rats; in vitro small-intestine enzyme assays
Compared with
Control animals
Main outcome
Digestive enzyme activity
Authors' conclusion
Livagen is weakly hydrolyzed; after oral administration enzyme activity fell in young rats and rose in old rats, approaching the young control level.
Limitations
Animal and in vitro study; numbers per group not stated.
PubMed 16075683
✓ Positivein vitroBull Exp Biol Med · 2002

Effects of Livagen peptide on chromatin activation in lymphocytes from old people.

Cells / labIn vitro chromatin study

In cultured lymphocytes from old people, Livagen activated ribosomal genes and decondensed pericentromeric heterochromatin, a chromatin-level change with no clinical endpoint measured.

Studied
Cultured lymphocytes from old people
Main outcome
Ribosomal gene activity, heterochromatin parameters
Authors' conclusion
Livagen induced activation of ribosomal genes and decondensation of heterochromatin, i.e. de-heterochromatinization (activation) of chromatin in lymphocytes from old people.
Limitations
In vitro cell study; sample size not stated in abstract.
PubMed 12533768DOI
✓ Positivein vitroBull Exp Biol Med · 2004

Effects of short peptides on lymphocyte chromatin in senile subjects.

Number of subjects not stated; leukocytes from subjects aged 75-88In vitro study of five short peptides (Vilon, Epithalon, Livagen, Prostamax, Cortagen) on chromatin

In leukocytes from subjects aged 75-88, Livagen and four related peptides activated ribosome genes and decondensed tightly packed chromatin.

Studied
Leukocytes from subjects aged 75-88 years
Compared with
Untreated cells
Main outcome
Ribosome gene activity and chromatin condensation
Authors' conclusion
All peptides activated ribosome genes and decondensed chromatin; Epithalon, Livagen and Prostamax decondensed chromosome 1 pericentromeric chromatin.
Limitations
In vitro; not specific to Prostamax; no clinical outcome.
PubMed 15085253DOI
✓ Positivein vitroGeorgian Med News · 2006

Anti-aging peptide bioregulators induce reactivation of chromatin.

Cells / labIn vitro study of Epitalon, Livagen and Vilon

In lymphocytes from people aged 75-88, Livagen (with epitalon and vilon) reactivated ribosomal genes and unwound total heterochromatin.

Studied
Cultured lymphocytes from old (75-88 yr) people
Main outcome
Structural and facultative heterochromatin
Authors' conclusion
Epitalon, Livagen and Vilon reactivated ribosomal genes and deheterochromatinized chromatin; Epitalon and Livagen (not Vilon) decondensed pericentromeric heterochromatin of chromosomes 1 and 9.
Limitations
In vitro cell study; sample size not stated in abstract.
PubMed 16705247
✓ Positivein vitroAnn N Y Acad Sci · 2007

Activation of pericentromeric and telomeric heterochromatin in cultured lymphocytes from old individuals.

Cells / labIn vitro study of CoCl2 and Livagen, alone and combined

In cultured lymphocytes from 80-91-year-olds, Livagen induced chromatin decondensation and modified cobalt-chloride-related chromosome changes.

Key resultLivagen decreased CoCl2-induced changes by 3.4 +/- 0.6% (control group 4.2 +/- 0.7%); CoCl2 raised chromosomal aberrations in old donors (P < 0.05)
Studied
Cultured lymphocytes from 80- to 91-year-old donors and 18- to 30-year-old controls
Compared with
Young control group
Main outcome
Total heterochromatin, chromosome instability, sister chromatid exchanges
Authors' conclusion
Livagen could reactivate (deheterochromatinize) chromatin in lymphocytes of aged individuals; Co2+ ions and Livagen target different chromosomal regions.
Limitations
In vitro cell study; donor numbers not stated in abstract.
PubMed 17460203DOI
✓ Positivein vitroGeorgian Med News · 2017

[EVALUATION OF GENOMIC PARAMETERS IN DUCTAL BREAST CANCER PATIENTS AND THE ABILITY OF IT'S CORRECTION].

Cells / labIn vitro study of DNA damage, chromosomal abnormalities and SCEs with Livagen and cobalt ions

In lymphocyte cultures from ductal breast cancer patients, Livagen with cobalt ions reduced DNA single-strand breaks, chromosomal abnormalities and chromatin condensation.

Studied
Lymphocyte cultures from patients with ductal breast cancer
Main outcome
DNA single strand breaks, chromosomal abnormalities, sister chromatid exchanges
Authors' conclusion
Livagen and cobalt as modifying agents had a protective effect on all studied parameters in lymphocytes of ductal breast cancer patients.
Limitations
In vitro lymphocyte study; no numbers given in the abstract.
PubMed 28574395
✓ Positivein vitroAdv Gerontol · 2002

[Functional morphology of an organotypic liver culture exposed to the peptide livagen].

Cells / labIn vitro immunocytochemical and morphometric analysis

In organotypic rat liver culture, Livagen stimulated structural and functional markers of hepatocyte regeneration.

Studied
Organotypic liver culture
Main outcome
Functional morphology of liver culture
Authors' conclusion
The tetrapeptide livagen stimulated structural and functional homeostasis of cell populations in the liver culture, stabilizing morphology and reinforcing regeneration processes.
Limitations
In vitro culture study; no quantitative data in the abstract.
PubMed 12577697
✓ Positivein vitroGeorgian Med News · 2014

[Genomic instability in atherosclerosis].

Cells / labCytogenetic study of cultured lymphocytes with and without Livagen, cobalt ions, or both

In lymphocyte cultures from atherosclerosis patients aged 80+, Livagen alone or with cobalt ions normalised raised chromosomal instability markers (laboratory cell study, no clinical outcome).

Studied
Lymphocyte cultures from patients with atherosclerosis aged 80 years and older, with healthy cultures from the same age group and from 30-35 year-olds as controls
Compared with
Lymphocyte cultures of healthy people of two age groups
Main outcome
Chromosome aberration, aneuploidy and polyploidy
Authors' conclusion
Livagen alone and with cobalt ions was reported to normalise altered genomic indicators in atherosclerosis cells; the authors infer efficacy in prevention of atherosclerosis.
Limitations
Cultured cells only; no patient was treated, so the prevention claim is an extrapolation.
PubMed 25541832
~ Mixedin vitroIzv Akad Nauk Ser Biol · 2003

[Effect of new peptide bioregulators livagen and epitalon on enkephalin-degrading enzymes in human serum].

Cells / labIn vitro enzyme assay and radioreceptor binding

Livagen inhibited enkephalin-degrading enzymes in human serum in vitro (IC50 20 microM) but did not bind mu- or delta-opioid receptors in rat brain membranes.

Key resultIC50 of Livagen 20 microM vs 500 microM for Epitalon; no binding to mu- or delta-opioid receptors
Studied
Human serum enzymes and rat brain membrane fractions
Compared with
Epitalon; puromycin, leupeptin and D-PAM as reference inhibitors
Main outcome
Inhibition of enkephalin hydrolysis; opioid receptor binding
Authors' conclusion
Livagen and Epitalon inhibited enkephalin-degrading enzymes from human serum, Livagen more efficiently, without interacting with the opioid receptors tested.
Limitations
Biochemical in vitro assay only; no whole-organism or clinical data.
PubMed 12942748
✓ Positivein vitroGeorgian Med News · 2007

[Variability of radiation-induced adaptive response in old age individuals and their correction by Peptide bioregulator -Livagen].

Cells / labIn vitro radiation adaptive-response assay with Livagen as a corrective agent

In PHA-stimulated lymphocytes from 72-86 year-old donors, a corrective effect of Livagen on radiation adaptive response was observed (cell study; abstract gives no numbers).

Studied
Cultured lymphocytes from 72-86 year-old and 30-40 year-old people
Compared with
Cells of 30-40 year-old individuals
Main outcome
Adaptive response to low-dose gamma-rays and copper chloride damage
Authors' conclusion
Cells from aged individuals kept the radiation adaptive response, and a corrective activity of Livagen was observed.
Limitations
Cultured cells; no quantitative results in the abstract.
PubMed 17921545
? Inconclusivein vitroGeorgian Med News · 2014

[Effect of peptide bioregulator and cobalt ions on the activity of NORs and associations of acrocentric chromosomes in lymphocytes of patients with hypertrophic cardiomyopathy and their relatives].

Cells / labCytogenetic study with Livagen alone or combined with cobalt ions

In lymphocytes from patients with hypertrophic cardiomyopathy and relatives, Livagen with cobalt ions increased NOR activity and acrocentric chromosome associations, read by the authors as chromatin decondensation (cell study, no clinical outcome).

Studied
Lymphocyte cultures from patients with hypertrophic cardiomyopathy and their relatives
Main outcome
Nucleolar organizer region activity; associations of acrocentric chromosomes
Authors' conclusion
Authors conclude Livagen and cobalt ions decondense heterochromatinized chromatin in these cells and suggest possible therapeutic relevance.
Limitations
Cultured cells; the clinical meaning of the chromosome changes is unproven.
PubMed 25341254

Verdicts are judged on each paper's own main outcome; grades run from A (strong human evidence) to D (little or none). Details are read from the abstracts, and figures are reproduced only from openly licensed full texts. Not medical advice.